Matthew A. Lakins

Matthew A. Lakins

Auto-generated profile, based on publicly available information

Matthew A. Lakins

F-Star Therapeutics, Babraham Research Campus, Cambridgeshire, United Kingdom. 3

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
MLMatthew A. Lakins
Matthew A. Lakins
EGEhsan Ghorani
Ehsan Ghorani
HMHafsa Munir
Hafsa Munir
CMCarla P. Martins
Carla P. Martins
JSJacqueline D Shields
Jacqueline D Shields
Tumours have developed strategies to interfere with most steps required for anti-tumour immune responses. Although many populations contribute to anti-tumour responses, tumour-infiltrating cytotoxic T cells dominate, hence, many suppressive strategies act to inhibit these. Tumour-associated T cells are frequently restricted to stromal zones rather than tumour islands, raising the possibility that the tumour microenvironment, where crosstalk between malignant and “normal” stromal cells exists, may be critical for T cell suppression. We provide evidence of direct interactions between stroma and T cells driving suppression, showing that cancer-associated fibroblasts (CAFs) sample, process and cross-present antigen, killing CD8+T cells in an antigen-specific, antigen-dependent manner via PD-L2 and FASL. Inhibitory ligand expression is observed in CAFs from human tumours, and neutralisation of PD-L2 or FASL reactivates T cell cytotoxic capacity in vitro and in vivo. Thus, CAFs support T cell suppression within the tumour microenvironment by a mechanism dependent on immune checkpoint activation.

1 August 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MLMatthew A. Lakins
Matthew A. Lakins
AKAlexander Koers
Alexander Koers
RGRaffaella Giambalvo
Raffaella Giambalvo
JMJose Munoz-Olaya
Jose Munoz-Olaya
RHRobert Hughes
Robert Hughes
NBNeil Brewis
Neil Brewis
Purpose: With the increased prevalence in checkpoint therapy resistance, there remains a significant unmet need for additional therapies for relapsing or refractory cancer patients. We have developed FS222, a bispecific tetravalent antibody targeting CD137 and PD-L1 to induce T cell activation to eradicate tumours without the current toxicity and efficacy limitations seen clinically. Experimental Design: A bispecific antibody (FS222) was developed by engineering CD137 binding sites into the Fc region of a PD-L1 IgG1 mAb. T cell activation by FS222 was investigated using multiple in vitro assays. The anti-tumour efficacy, survival benefit, pharmacodynamics and liver pharmacology of a murine surrogate molecule were assessed in syngeneic mouse tumour models. Toxicology and the pharmacokinetic/pharmacodynamic profile of FS222 was investigated in a non-human primate dose-range finding study. Results: We demonstrated simultaneous binding of CD137 and PD-L1 and showed potent T cell activation across CD8+ T cell activation assays in a PD-L1-dependent manner with FS222. FS222 also activated T cells in a human primary mixed lymphocyte reaction assay, with greater potency than the monospecific mAb combination. FS222 showed no signs of liver toxicity up to 30 mg/kg in a non-human primate dose-range finding study. A surrogate molecule caused significant tumour growth inhibition and survival benefit, concomitant with CD8+ T cell activation, in CT26 and MC38 syngeneic mouse tumour models. Conclusions: By targeting CD137 agonism to areas of PD-L1 expression, predominantly found in the tumour microenvironment, FS222 has the potential to leverage a focused, potent and safe immune response augmenting the PD-(L)1 axis blockade.

24 July 2009 in Journal of Microscopy
Verified
Journal Article
Closed access
PDF file
MLM.A. Lakins
M.A. Lakins
JMJ.L. Marrison
J.L. Marrison
POP.J. O’tOole
P.J. O’tOole
MWM.W. VAN DER Woude
M.W. VAN DER Woude

1 August 2024 in Cancer Research Communications
Verified
Journal Article
Open access
CICharlotte J. Imianowski
Charlotte J. Imianowski
PKPaula Kuo
Paula Kuo
SWSarah K. Whiteside
Sarah K. Whiteside
TLTeresa von Linde
Teresa von Linde
AWAlexander J. Wesolowski
Alexander J. Wesolowski
RRRahul Roychoudhuri
Rahul Roychoudhuri
Regulatory T cells (Treg) are highly enriched within many tumors and suppress immune responses to cancer. There is intense interest in reprogramming Tregs to contribute to antitumor immunity. OX40 and CD137 are expressed highly on Tregs, activated and memory T cells, and NK cells. In this study, using a novel bispecific antibody targeting mouse OX40 and CD137 (FS120m), we show that OX40/CD137 bispecific agonism induces potent antitumor immunity partially dependent upon IFNγ production by functionally reprogrammed Tregs. Treatment of tumor-bearing animals with OX40/CD137 bispecific agonists reprograms Tregs into both fragile Foxp3+ IFNγ+ Tregs with decreased suppressive function and lineage-instable Foxp3− IFNγ+ ex-Tregs. Treg fragility is partially driven by IFNγ signaling, whereas Treg instability is associated with reduced IL2 responsiveness upon treatment with OX40/CD137 bispecific agonists. Importantly, conditional deletion of Ifng in Foxp3+ Tregs and their progeny partially reverses the antitumor efficacy of OX40/CD137 bispecific agonist therapy, revealing that reprogramming of Tregs into IFNγ-producing cells contributes to the anti-tumor efficacy of OX40/CD137 bispecific agonists. These findings provide insights into mechanisms by which bispecific agonist therapies targeting costimulatory receptors highly expressed by Tregs potentiate antitumor immunity in mouse models. Significance: The bispecific antibody FS120, an immunotherapy currently being tested in the clinic, partially functions by inducing anti-tumor activity of Tregs, which results in tumor rejection.

12 August 2024
Verified
Other
Open access
CICharlotte J. Imianowski
Charlotte J. Imianowski
PKPaula Kuo
Paula Kuo
SWSarah K. Whiteside
Sarah K. Whiteside
TLTeresa von Linde
Teresa von Linde
AWAlexander J. Wesolowski
Alexander J. Wesolowski
RRRahul Roychoudhuri
Rahul Roychoudhuri
Regulatory T cells (Treg) are highly enriched within many tumors and suppress immune responses to cancer. There is intense interest in reprogramming Tregs to contribute to antitumor immunity. OX40 and CD137 are expressed highly on Tregs, activated and memory T cells, and NK cells. In this study, using a novel bispecific antibody targeting mouse OX40 and CD137 (FS120m), we show that OX40/CD137 bispecific agonism induces potent antitumor immunity partially dependent upon IFNγ production by functionally reprogrammed Tregs. Treatment of tumor-bearing animals with OX40/CD137 bispecific agonists reprograms Tregs into both fragile Foxp3+ IFNγ+ Tregs with decreased suppressive function and lineage-instable Foxp3− IFNγ+ ex-Tregs. Treg fragility is partially driven by IFNγ signaling, whereas Treg instability is associated with reduced IL2 responsiveness upon treatment with OX40/CD137 bispecific agonists. Importantly, conditional deletion of Ifng in Foxp3+ Tregs and their progeny partially reverses the antitumor efficacy of OX40/CD137 bispecific agonist therapy, revealing that reprogramming of Tregs into IFNγ-producing cells contributes to the anti-tumor efficacy of OX40/CD137 bispecific agonists. These findings provide insights into mechanisms by which bispecific agonist therapies targeting costimulatory receptors highly expressed by Tregs potentiate antitumor immunity in mouse models.Significance:The bispecific antibody FS120, an immunotherapy currently being tested in the clinic, partially functions by inducing anti-tumor activity of Tregs, which results in tumor rejection.

28 March 2025
Verified
Other
Open access
CICharlotte J. Imianowski
Charlotte J. Imianowski
PKPaula Kuo
Paula Kuo
SWSarah K. Whiteside
Sarah K. Whiteside
TLTeresa von Linde
Teresa von Linde
AWAlexander J. Wesolowski
Alexander J. Wesolowski
RRRahul Roychoudhuri
Rahul Roychoudhuri
Supplementary Figure 3: Increased IL-2 expression by conventional CD4+ and CD8+ T cells with FS120m treatment. Representative plots (left) and replicate measurements (right) of IL-2+ CD4+ Tconv cells and CD8+ T cells in the spleen and draining lymph nodes on day 18 post tumor implantation. *** P ≤ 0.001, **** P ≤ 0.0001. Unpaired Student’s t test. Bars and error are mean and s.e.m.